The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s (NOVOb.CO), weight-loss and diabetes drugs.
The health regulator said it had received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to patients incorrectly self-administering the compounded drug and healthcare providers miscalculating doses.
The FDA flagged the higher risk to patients from the use of compounded drugs, which may contain additional ingredients, and may contribute to potential medication errors. It urged healthcare providers and compounders to provide the appropriate syringe size and counsel patients on how to measure the dose.
Tags: Compounding Counterfeit New Drug Trends Overdoses Patient Harm Wegovy
